Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1(5):e259–81. doi: 10.1016/S2214-109X(13)70089-5 25104492

2. Sacco RL. Risk factors for TIA and TIA as a risk factor for stroke. Neurology. 2004;62(8 Suppl 6):S7–11.

3. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Clinical Guideline 181. London: National Clinical Guideline Centre; 2014.

4. National Institute for Health and Clinical Excellence. Hypertension: the clinical management of primary hypertension in adults. Clinical Guideline 127. London: National Clinical Guideline Centre; 2011.

5. National Institute for Health and Clinical Excellence. Atrial fibrillation: the management of atrial fibrillation. Clinical Guideline 180. London: National Clinical Guideline Centre; 2014.

6. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(3):CD001927. doi: 10.1002/14651858.CD001927.pub2 16034869

7. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;(3):CD006186. doi: 10.1002/14651858.CD006186.pub2 17636831

8. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289(19):2534–44. doi: 10.1001/jama.289.19.2534 12759325

9. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816. doi: 10.1002/14651858.CD004816.pub5 23440795

10. Wang W, Zhang B. Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS ONE. 2014;9(3):e92388. doi: 10.1371/journal.pone.0092388 24643199

11. Heneghan C, Perera R, Mant D, Glasziou P. Hypertension guideline recommendations in general practice: awareness, agreement, adoption, and adherence. Br J Gen Pract. 2007;57(545):948–52. doi: 10.3399/096016407782604965 18252069

12. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3(8):e003423. doi: 10.1136/bmjopen-2013-003423 23996822

13. Khatib R, Schwalm J-D, Yusuf S, Haynes RB, McKee M, Khan M, et al. Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. PLoS ONE. 2014;9(1):e84238. doi: 10.1371/journal.pone.0084238 24454721

14. Koivisto P, Koivisto U, Miettinen T, Kontula K. Diagnosis of heterozygous familial hypercholesterolemia. DNA analysis complements clinical examination and analysis of serum lipid levels. Arterioscler Thromb Vasc Biol. 1992;12(5):584–92.

15. Missault L, Witters N, Imschoot J. High cardiovascular risk and poor adherence to guidelines in 11 069 patients of middle age and older in primary care centres. Eur J Cardiovasc Prev Rehabil. 2010;17(5):593–8. doi: 10.1097/HJR.0b013e328339cc86 20389248

16. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.e4. doi: 10.1016/j.amjmed.2009.11.025 20609686

17. Palm F, Kleemann T, Dos Santos M, Urbanek C, Buggle F, Safer A, et al. Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS2, CHA2DS2-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol. 2013;20(1):117–23. doi: 10.1111/j.1468-1331.2012.03804.x 22788384

18. Partington SL, Abid S, Teo K, Oczkowski W, O’Donnell MJ. Pre-admission warfarin use in patients with acute ischemic stroke and atrial fibrillation: the appropriate use and barriers to oral anticoagulant therapy. Thromb Res. 2007;120(5):663–9. doi: 10.1016/j.thromres.2006.12.019 17434577

19. Roccatagliata D, Avanzini F, Monesi L, Caimi V, Lauri D, Longoni P, et al. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients’ risk level. Vasc Health Risk Manag. 2006;2(4):507–14. 17323606

20. Moran GM, Calvert M, Feltham MG, Marshall T. Retrospective case review of missed opportunities for primary prevention of stroke and TIA in primary care: protocol paper. BMJ Open. 2014;4:e006622. doi: 10.1136/bmjopen-2014-006622 25387760

21. IMS Health. Ethics. London: IMS Health; 2015 [cited 2016 Oct 15]. Available from: http://csdmruk.cegedim.com/our-data/ethics.shtml.

22. The Health Improvement Network. Partnership. London: CSD Health Research; 2016 [cited 2016 Oct 15]. Available from: http://www.thin-uk.com/.

23. Ruigomez A, Martin-Merino E, Rodriguez LA. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf. 2010;19(6):579–85. doi: 10.1002/pds.1919 20131328

24. In Practice Systems. The Health Improvement Network (THIN). London: In Practice Systems; 2016 [cited 2016 Oct 15]. Available from: http://www.inps.co.uk/vision/health-improvement-network-thin.

25. IMS Health. Statistics. London: IMS Health; 2005 [cited 2016 Oct 15]. Available from: http://csdmruk.cegedim.com/our-data/statistics.shtml.

26. Maguire A, Blak B, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf. 2009;18(1):76–83. doi: 10.1002/pds.1688 19065600

27. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. Clinical Guideline 36. London: National Clinical Guideline Centre; 2006.

28. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. Clinical Guideline 67. London: National Clinical Guideline Centre; 2008.

29. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503. doi: 10.1016/S0140-6736(07)61233-1 17693178

30. Health and Social Care Information Centre. Read codes. London: Health and Social Care Information Centre; 2016 [cited 2016 Oct 15]. Available from: http://systems.hscic.gov.uk/data/uktc/readcodes/index_html.

31. Health and Social Care Information Centre. QOF business rules version 27. Leeds: Primary Care Commissioning; 2016 [cited 2016 Oct 15]. Available from: http://www.pcc-cic.org.uk/article/qof-business-rules-v27.

32. Midlov P, Ekesbo R, Johansson L, Gerward S, Persson K, Nerbrand C, et al. Barriers to adherence to hypertension guidelines among GPs in southern Sweden: a survey. Scand J Prim Health Care. 2008;26(3):154–9. doi: 10.1080/02813430802202111 18609250

33. CSD Medical Research UK. THIN data guide for researchers. London: CSD Medical Research UK; 2014. 114 p.

34. IMS Health. Quality assurance. London: IMS Health; 2015 [cited 2016 Oct 15]. Available from: http://www.epic-uk.org/our-data/data-quality.shtml.

35. London Datastore. Office for National Statistics (ONS) population estimates, borough and ward. London: London Datastore; 2016 [cited 2016 Oct 15]. Available from: http://data.london.gov.uk/dataset/office-national-statistics-ons-population-estimates-borough.

36. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005;366(9499):1773–83. doi: 10.1016/S0140-6736(05)67702-1 16298214

37. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–223. doi: 10.1016/S0140-6736(12)61689-4 23245608

38. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128. doi: 10.1016/S0140-6736(12)61728-0 23245604

39. National Health Service. Prescription cost analysis, England–2013 [NS]. London: National Health Service; 2014 [cited 2016 Oct 15]. Available from: http://www.hscic.gov.uk/catalogue/PUB13887.

40. United Nations Department of Economic and Social Affairs. World population prospects, the 2015 revision. United Nations Department of Economic and Social Affairs; 2015 [cited 2016 Oct 15]. Available from: http://esa.un.org/wpp/Excel-Data/population.htm.

41. AB E, Denig P, Van Vliet T, Dekker J. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract. 2009;10(1):24.

42. Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract. 2003;53(494):684–9. 15103875

43. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21(4):464–74. doi: 10.1177/2047487314525531 24623264

44. Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011;40(6):675–83. doi: 10.1093/ageing/afr097 21821732

45. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840–4. 8114238

46. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2013;129(8):837–47. doi: 10.1161/CIRCULATIONAHA.113.005119 24345399

47. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10):1760–4. 8841325

48. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983–8. 1866765

49. Lawes CMM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8. doi: 10.1016/S0140-6736(08)60655-8 18456100

50. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–65. 10535437

51. Gale N, Greenfield S, Gill P, Gutridge K, Marshall T. Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam Pract. 2011;12:59. doi: 10.1186/1471-2296-12-59 21703010

52. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Reiner Ž, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010;17(5):530–40. doi: 10.1097/HJR.0b013e3283383f30 20577089

53. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10–17. doi: 10.1161/01.HYP.0000103630.72812.10 14638619

54. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8(2 Suppl 1):S12–20.